Sanofi's Cablivi, or caplacizumab-yhdp, has been approved by the FDA for use in combination with plasma exchange and immunosuppression as a treatment for adult patients with acquired thrombotic thrombocytopenic purpura.
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information
that is changing your industry today, hand-curated by our professional editors from
thousands of sources and delivered straight to your inbox.